Cyclospora Outbreak Response: Recognition, Diagnosis, and Treatment

This activity prepares healthcare professionals to recognize and respond to cyclosporiasis during the 2026 United States outbreak and during future cyclosporiasis seasons. The scope extends from clinical recognition through diagnosis, treatment, reporting, and operational recall response, and it is organized so that each profession receives instruction calibrated to its own decision authority.

The activity addresses a documented practice gap. Diagnosis of cyclosporiasis depends on deliberate clinical suspicion followed by an organism-specific test request, because routine ova-and-parasite examination and some gastrointestinal PCR panels do not reliably detect the parasite. Detection is further complicated by low and intermittent oocyst shedding, so that a single negative specimen does not exclude infection. During 2026, domestically acquired case counts rose substantially above prior-year levels, and CDC directed a Health Alert Network advisory specifically to clinicians, laboratorians, and public health practitioners.

The relevance to patient care is direct. Earlier recognition supports earlier treatment of an illness that may otherwise persist for a month or longer and may follow a remitting-relapsing course. Complete and timely reporting supports the cluster detection and traceback activities that identify a contaminated vehicle and interrupt continued exposure.

Outbreak case counts, implicated products, geographic distribution, and active investigations are operational data that change rapidly. Learners should treat the epidemiologic figures presented here as accurate as of the stated dates and should consult current CDC and Food and Drug Administration (FDA) sources before acting on product-specific information.

Upon completion of this activity, the learner will be able to:

1. Differentiate cyclosporiasis from other causes of persistent or relapsing diarrhea using clinical, exposure, severity, and health-history findings.
2. Select a Cyclospora-specific testing and specimen strategy that accounts for test-menu limitations and intermittent oocyst shedding.
3. Formulate an evidence-based treatment and supportive-care plan that addresses TMP-SMX safety, special populations, hydration, follow-up, and limited alternatives.
4. Coordinate referral, jurisdiction-specific reporting, exposure documentation, laboratory communication, practice-setting precautions, and verified recall actions within professional role boundaries.